DOLE
20.12.2022 17:17:38 CET | Business Wire | Press release
Dole plc (NYSE: DOLE) announced today the release of its first sustainability report since the 2021 merger of Total Produce plc and Dole Food Company. Building on its historical achievements, this report sets out the organization’s refreshed sustainability framework and offers a new set of environmental, social and governance (ESG) goals through 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005564/en/
The Dole Way, Dole’s sustainability framework, focuses on robust governance and three core pillars—For Nature, For People and For Food—covering environmental, ethical and social and nutrition related issues. These three pillars incorporate key areas identified as being most material to the impact of our business’ operations.
- For Nature: By committing to the Science Based Target Initiative, Dole plc places climate action at the forefront of its priorities along with water stewardship, biodiversity, waste management and packaging reduction and innovation.
- For People: Directly employing 38,500 people globally while partnering with third party growers worldwide, Dole is committed to being an employer of choice, supporting local communities and protecting human rights across its supply chains.
- For Food: Dole is committing to promoting healthy nutrition and improving access to fresh produce through partnerships and donations.
“Dole has built market-leading positions across a wide range of fresh fruit and vegetable segments by incorporating sustainability into their growth models,” stated Rory Byrne, Dole plc Chief Executive Officer. “As our climate is changing, we are focused on identifying the related risks, adapting to the effects on our operations and minimizing our own impacts. We also recognize and relish the special role we can play in improving people’s lives and the contribution Dole can make to promoting good health and wellbeing.”
The report also lays the foundation for the promotion of regenerative farming practices across Dole’s own operations as well as on associated farms which will support the business’ ambitious climate goals.
Highlights of the report include Dole plc’s:
- First global carbon footprint collection including measuring and managing scope 1, scope 2 and scope 3 emissions resulting in a reduction of 4% in Scope 1 and 2 emissions (2021 over 2020)
- Investment in Renewal Energy with two 2.8 megawatt wind turbines in Dole Fresh Vegetables in Soledad, California and installed new solar panel system at Belfast, Ireland site with a capacity of 120 kWp
- Recognition by American-Costa Rican Chamber of Commerce (AmCham) of Dole affiliate, Standard Fruit Company de Costa Rica S.A., for their innovative project "De la Mano con Dole." The project positively impacts the social development of employees and their families using the Business Multidimensional Poverty Index (bMPI) methodology which measures poverty beyond only per capita income - to include access to health, education, housing, work, social protection and 16 other key indicators.
Xavier Roussel, Dole plc’s Chief Marketing and Sustainability officer, stated, “Although fresh produce has a low environmental footprint in comparison to other food sources, there is still much to do to further decrease our impacts and adapt to the effects of climate change. We are addressing those challenges for the long term with likeminded partners along the supply chain. Our vertically integrated business model allows us to research much in our own operations before expanding to our associated farmers which is instrumental to lead change in the industry.”
Adding, “Caring for our most important resources: our people, the nature around us and the food we deliver to the world is our way to contribute to society and will set us up for continued success.”
To view the full Dole plc 2022 Corporate Responsibility & Sustainability Report click here or visit www.doleplc.com.
About Dole plc
A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place. For more information, please visit www.doleplc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
